Erasca, Inc. (ERAS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US29479A1088
Erasca, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -140.91 m USD |
| EBIT | -124.55 m USD |
| Net income | -124.55 m USD |
| Diluted EPS – continuing operations | -0.44 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Erasca, Inc.
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
More stocks
- Beijing Enterprises Holdings Ltd (392.HK)
- Hirose Electric Co Ltd (6806.T)
- HA Sustainable Infrastructure Capital, Inc. (HASI)
- Nippon Television Holdings Inc (9404.T)
- Yifeng Pharmacy (603939.SS)
- CREDIT ACCEPTANCE CORP (CACC)
- Hangzhou Great Star Industrial Co Ltd (002444.SZ)
- COUSINS PROPERTIES INC (CUZ)
- Applied Digital Corp. (APLD)
- China Resources Gas Group Ltd (1193.HK)
- Suzhou Inovance Automotive Co., Ltd. (301656.SZ)
- DiaSorin SpA (DIA.MI)
Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.